ClinicalTrials.gov URL
Acknowledgement
30 days
Gilead
Gilead Sciences
U.S. Army Medical Research and Development Command
EA Policies for Disease / Category
COVID-19 Information
COVID-19 Resource Page
Expanded Access Remdesivir (RDV; GS-5734™) - for DOD/military personnel only
Emergency Access to Remdesivir Outside of Clinical Trials
An Open Letter from our Chairman and CEO (March 28, 2020)
An Update on COVID-19 from our Chairman & CEO (April 4, 2020)
"Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations."
Stage
Phase 2
Phase 3
Expanded Access
Company Type
Late Onset Intervention
Early Onset Intervention